This department is offering the Countermeasures Against Chemical Threats (CounterACT) Grant to optimize therapeutic lead compounds for potential development into treatments for chemical threats. Projects should focus on small molecule or biologic compounds with established biological activity, potency, and safety profiles. Research supported includes animal model development, efficacy testing, assay validation, manufacturing, and toxicity studies. Applicants are required to have a previously identified lead compound to apply. Annual milestones and translational study plans are essential components of funded projects. Deadline for applications is Sep 14, 2021.
Opportunity ID: 309957
General Information
Document Type: | Grants Notice |
Funding Opportunity Number: | PAR-19-040 |
Funding Opportunity Title: | Countermeasures Against Chemical Threats (CounterACT): Optimization of Therapeutic Lead Compounds (U01 Clinical Trial Optional) |
Opportunity Category: | Discretionary |
Opportunity Category Explanation: | – |
Funding Instrument Type: | Cooperative Agreement |
Category of Funding Activity: | Education Environment Health |
Category Explanation: | – |
Expected Number of Awards: | – |
Assistance Listings: | 93.113 — Environmental Health |
Cost Sharing or Matching Requirement: | No |
Version: | Synopsis 1 |
Posted Date: | Oct 26, 2018 |
Last Updated Date: | Oct 26, 2018 |
Original Closing Date for Applications: | Sep 14, 2021 |
Current Closing Date for Applications: | Sep 14, 2021 |
Archive Date: | Oct 20, 2021 |
Estimated Total Program Funding: | – |
Award Ceiling: | – |
Award Floor: | – |
Eligibility
Eligible Applicants: | County governments Public and State controlled institutions of higher education State governments Others (see text field entitled “Additional Information on Eligibility” for clarification) Special district governments Public housing authorities/Indian housing authorities Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education Small businesses Independent school districts For profit organizations other than small businesses City or township governments Native American tribal governments (Federally recognized) |
Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
Additional Information
Agency Name: | National Institutes of Health |
Description: | This Funding Opportunity Announcement (FOA) encourages applications for Countermeasures Against Chemical Threats (CounterACT) Cooperative Agreement (U01) Research Projects for research on the optimization of small molecule or biologic compounds that are excellent candidates for therapeutic development. The mission of the CounterACT Program is to foster and support research and development of new and improved therapeutics for chemical threats. Chemical threats are toxic chemicals that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include traditional chemical warfare agents, toxic industrial chemicals, pharmaceutical-based agents, and pesticides. A previously identified lead compound is required to be eligible for this funding opportunity. In this regard, lead compounds are defined as biologically active compounds or hits where affinity, potency, target selectivity, and preliminary safety have been established. The scope of research supported by this FOA includes development of appropriate human-relevant animal models and generation of in vivo efficacy data consistent with the intended use of the product in humans. It also includes bioanalytical assay development and validation, laboratory-scale and scaleable manufacturing of the product, and non-GLP toxicity and pharmacology studies. The scope of this FOA encompasses Technical Readiness Levels (TRLs) 4-5 – see TRLs. Each project must include annual milestones that create discrete go or no-go decision points in a progressive translational study plan. |
Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PAR-19-040.html |
Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV Email:FBOWebmaster@OD.NIH.GOV |
Version History
Version | Modification Description | Updated Date |
---|---|---|
Related Documents
There are no related documents on this grant.
Packages
Agency Contact Information: | NIH OER Webmaster FBOWebmaster@OD.NIH.GOV Email: FBOWebmaster@OD.NIH.GOV |
Who Can Apply: | Organization Applicants |
Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
---|---|---|---|---|---|---|
FORMS-E | Use for due dates on or before May 24, 2020 | PKG00245881 | Aug 10, 2019 | May 24, 2020 | View | |
FORMS-F | Use for due dates on or after May 25, 2020 | PKG00259485 | Aug 10, 2019 | Sep 14, 2021 | View |
Package 1
Mandatory forms
309957 RR_SF424_2_0-2.0.pdf
309957 PHS398_CoverPageSupplement_4_0-4.0.pdf
309957 RR_OtherProjectInfo_1_4-1.4.pdf
309957 PerformanceSite_2_0-2.0.pdf
309957 RR_KeyPersonExpanded_2_0-2.0.pdf
309957 PHS398_ResearchPlan_4_0-4.0.pdf
Optional forms
309957 RR_Budget_1_4-1.4.pdf
309957 RR_SubawardBudget30_1_4-1.4.pdf
309957 PHS398_ModularBudget_1_2-1.2.pdf
309957 PHS_AssignmentRequestForm_2_0-2.0.pdf
Package 2
Mandatory forms
309957 RR_SF424_2_0-2.0.pdf
309957 PHS398_CoverPageSupplement_5_0-5.0.pdf
309957 RR_OtherProjectInfo_1_4-1.4.pdf
309957 PerformanceSite_2_0-2.0.pdf
309957 RR_KeyPersonExpanded_2_0-2.0.pdf
309957 PHS398_ResearchPlan_4_0-4.0.pdf
309957 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf
Optional forms
309957 RR_Budget_1_4-1.4.pdf
309957 RR_SubawardBudget30_1_4-1.4.pdf
309957 PHS398_ModularBudget_1_2-1.2.pdf
309957 PHS_AssignmentRequestForm_3_0-3.0.pdf